10-K Filing

ARROWHEAD PHARMACEUTICALS, INC. CIK: 879407 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0001628280-23-040219`
Period End Date	20230930
Filing Date	20231129
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	arwr-20230930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 81 Income Statement 63 Cash Flow Statement 86 Stockholders Equity 28

Balance Sheet 81 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	290.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	290.00M	shares	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$110.89M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	107.31M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	105.96M	shares	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$184.43M	USD	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.58M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$1.41M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	105.96M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	107.31M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	-	USD	Point-in-time
Available-for-sale securities, at fair value	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$292.74M	USD	Point-in-time
Available-for-sale securities, at fair value	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	-	USD	Point-in-time
Held-to-maturity securities, at amortized cost	`HeldToMaturitySecuritiesCurrent`	$268.39M	USD	Point-in-time
Held-to-maturity securities, at amortized cost	`HeldToMaturitySecuritiesCurrent`	-	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$7.29M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$8.81M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$7.08M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$20.20M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$419.52M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$405.30M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$110.30M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$290.26M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$10.26M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$11.96M	USD	Point-in-time
Held-to-maturity securities, at amortized cost	`HeldToMaturitySecuritiesNoncurrent`	-	USD	Point-in-time
Held-to-maturity securities, at amortized cost	`HeldToMaturitySecuritiesNoncurrent`	$105.87M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$58.29M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$45.30M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$218.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$210.00K	USD	Point-in-time
Total Assets	`Assets`	$691.94M	USD	Point-in-time
Total Assets	`Assets`	$765.55M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$35.87M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.87M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$46.86M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$39.76M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$12.25M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$17.96M	USD	Point-in-time
Lease liabilities	`OperatingLeaseLiabilityCurrent`	$2.78M	USD	Point-in-time
Lease liabilities	`OperatingLeaseLiabilityCurrent`	$10.56M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$866.00K	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$74.10M	USD	Point-in-time
Other liabilities	`OtherLiabilitiesCurrent`	-	USD	Point-in-time
Other liabilities	`OtherLiabilitiesCurrent`	$435.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$138.85M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$105.46M	USD	Point-in-time
Lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$78.80M	USD	Point-in-time
Lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$104.61M	USD	Point-in-time
Deferred revenue, net of current portion	`ContractWithCustomerLiabilityNoncurrent`	$55.95M	USD	Point-in-time
Deferred revenue, net of current portion	`ContractWithCustomerLiabilityNoncurrent`	-	USD	Point-in-time
Liability related to the sale of future royalties	`RoyaltiesLiabilityNoncurrent`	$268.33M	USD	Point-in-time
Liability related to the sale of future royalties	`RoyaltiesLiabilityNoncurrent`	-	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$134.75M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$372.93M	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,312 and 105,960 shares	`CommonStockValue`	$198.00K	USD	Point-in-time
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,312 and 105,960 shares	`CommonStockValue`	$200.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$1.30B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$1.22B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-136.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-3.22M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.03B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-820.75M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$398.52M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$271.34M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$19.82M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$15.82M	USD	Point-in-time
Total noncontrolling interest and stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$461.78M	USD	Point-in-time
Total noncontrolling interest and stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Total noncontrolling interest and stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$287.16M	USD	Point-in-time
Total noncontrolling interest and stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$408.82M	USD	Point-in-time
Total Liabilities, Noncontrolling Interest and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$765.55M	USD	Point-in-time
Total Liabilities, Noncontrolling Interest and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$691.94M	USD	Point-in-time

Income Statement 63 line items

Line Item	Tag	Value	Unit	Period
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$240.74M	USD	Annual
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$138.29M	USD	Annual
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$243.23M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$206.34M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$353.19M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$297.31M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$80.98M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$124.43M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$92.55M	USD	Annual
Total operating expenses	`OperatingExpenses`	$445.74M	USD	Annual
Total operating expenses	`OperatingExpenses`	$421.74M	USD	Annual
Total operating expenses	`OperatingExpenses`	$287.32M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-149.04M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-205.00M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-178.51M	USD	Annual
Interest income	`InvestmentIncomeInterestAndDividend`	$6.12M	USD	Annual
Interest income	`InvestmentIncomeInterestAndDividend`	$5.03M	USD	Annual
Interest income	`InvestmentIncomeInterestAndDividend`	$15.30M	USD	Annual
Interest expense	`InterestExpense`	$18.33M	USD	Annual
Interest expense	`InterestExpense`	-	USD	Annual
Interest expense	`InterestExpense`	-	USD	Annual
Other, net	`OtherNonoperatingIncomeExpense`	$1.54M	USD	Annual
Other, net	`OtherNonoperatingIncomeExpense`	$2.07M	USD	Annual
Other, net	`OtherNonoperatingIncomeExpense`	$765.00K	USD	Annual
Total other (expense) income	`NonoperatingIncomeExpense`	$8.19M	USD	Annual
Total other (expense) income	`NonoperatingIncomeExpense`	$-1.49M	USD	Annual
Total other (expense) income	`NonoperatingIncomeExpense`	$5.80M	USD	Annual
Loss before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-172.71M	USD	Annual
Loss before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-206.49M	USD	Annual
Loss before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-140.85M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$2.00K	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$2.78M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$3.79M	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-140.85M	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-176.49M	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-209.28M	USD	Annual
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	Annual
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	$-4.00M	USD	Annual
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	$-431.00K	USD	Annual
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-140.85M	USD	Annual
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-176.06M	USD	Annual
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-205.28M	USD	Annual
Basic (in dollars per share)	`EarningsPerShareBasic`	$-1.92	USD	Annual
Basic (in dollars per share)	`EarningsPerShareBasic`	$-1.67	USD	Annual
Basic (in dollars per share)	`EarningsPerShareBasic`	$-1.36	USD	Annual
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.92	USD	Annual
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.36	USD	Annual
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.67	USD	Annual
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	103.75M	shares	Annual
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	105.43M	shares	Annual
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	106.75M	shares	Annual
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	106.75M	shares	Annual
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	103.75M	shares	Annual
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	105.43M	shares	Annual
Unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	Annual
Unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-2.96M	USD	Annual
Unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-87.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-67.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-122.00K	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-140.94M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-212.36M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-176.56M	USD	Annual

Cash Flow Statement 86 line items

Line Item	Tag	Value	Unit	Period
Net loss including noncontrolling interest	`ProfitLoss`	$-140.85M	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-176.49M	USD	Annual
Net loss including noncontrolling interest	`ProfitLoss`	$-209.28M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$76.67M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$78.13M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$120.89M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$12.49M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$8.27M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$10.42M	USD	Annual
(Accretion) amortization of note premiums/discounts	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-266.00K	USD	Annual
(Accretion) amortization of note premiums/discounts	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-2.91M	USD	Annual
(Accretion) amortization of note premiums/discounts	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$2.02M	USD	Annual
Non-cash interest expense on liability related to the sale of future royalties	`NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties`	-	USD	Annual
Non-cash interest expense on liability related to the sale of future royalties	`NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties`	-	USD	Annual
Non-cash interest expense on liability related to the sale of future royalties	`NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties`	$18.33M	USD	Annual
Net loss (gain) from investments	`GainLossOnInvestments`	$1.71M	USD	Annual
Net loss (gain) from investments	`GainLossOnInvestments`	-	USD	Annual
Net loss (gain) from investments	`GainLossOnInvestments`	$-4.43M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$9.41M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-1.41M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-8.85M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$360.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$19.29M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-11.60M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.63M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-6.59M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$33.00M	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$9.52M	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-14.96M	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$17.75M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$223.26M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-129.18M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-112.50M	USD	Annual
Operating lease, net	`IncreaseDecreaseInOperatingLeaseLiability`	$46.59M	USD	Annual
Operating lease, net	`IncreaseDecreaseInOperatingLeaseLiability`	$13.43M	USD	Annual
Operating lease, net	`IncreaseDecreaseInOperatingLeaseLiability`	$3.19M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$65.00K	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	-	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$-169.00K	USD	Annual
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-136.13M	USD	Annual
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$171.31M	USD	Annual
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-153.89M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$52.78M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$176.74M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$23.57M	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$240.70M	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$223.39M	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$246.14M	USD	Annual
Proceeds from sales and maturities of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$326.72M	USD	Annual
Proceeds from sales and maturities of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$270.75M	USD	Annual
Proceeds from sales and maturities of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$122.59M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-96.16M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-5.42M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-141.68M	USD	Annual
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$5.19M	USD	Annual
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$3.05M	USD	Annual
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$11.30M	USD	Annual
Proceeds from the sale of future royalties	`ProceedsFromSaleOfFutureRoyalties`	-	USD	Annual
Proceeds from the sale of future royalties	`ProceedsFromSaleOfFutureRoyalties`	-	USD	Annual
Proceeds from the sale of future royalties	`ProceedsFromSaleOfFutureRoyalties`	$250.00M	USD	Annual
Proceeds from investment in joint venture	`ProceedsFromContributedCapital`	-	USD	Annual
Proceeds from investment in joint venture	`ProceedsFromContributedCapital`	$60.00M	USD	Annual
Proceeds from investment in joint venture	`ProceedsFromContributedCapital`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$11.30M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$253.05M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$65.19M	USD	Annual
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-76.36M	USD	Annual
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$3.01M	USD	Annual
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$40.94M	USD	Annual
Effect of exchange rate on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-122.00K	USD	Annual
Effect of exchange rate on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-88.00K	USD	Annual
Effect of exchange rate on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-67.00K	USD	Annual
BEGINNING OR PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$110.89M	USD	Point-in-time
BEGINNING OR PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$184.43M	USD	Point-in-time
BEGINNING OR PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
BEGINNING OR PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.58M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$110.89M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$184.43M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.58M	USD	Point-in-time
Interest paid	`InterestPaidNet`	-	USD	Annual
Interest paid	`InterestPaidNet`	-	USD	Annual
Interest paid	`InterestPaidNet`	-	USD	Annual
Income Taxes Paid	`IncomeTaxesPaidNet`	$-2.00K	USD	Annual
Income Taxes Paid	`IncomeTaxesPaidNet`	$-2.00K	USD	Annual
Income Taxes Paid	`IncomeTaxesPaidNet`	-	USD	Annual

Stockholders Equity 28 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$461.78M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$287.16M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$408.82M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$120.89M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$78.13M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$76.67M	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$11.30M	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$3.05M	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$5.18M	USD	Annual
Exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	439,350.00	shares	Annual
Common stock - restricted stock units vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Common stock - restricted stock units vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Common stock - restricted stock units vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	Annual
Unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-2.96M	USD	Annual
Unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-87.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-67.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-122.00K	USD	Annual
Interest in joint venture	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$60.00M	USD	Annual
Net loss	`ProfitLoss`	$-140.85M	USD	Annual
Net loss	`ProfitLoss`	$-176.49M	USD	Annual
Net loss	`ProfitLoss`	$-209.28M	USD	Annual
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$461.78M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$287.16M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$408.82M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.